U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C21H26N6O2
Molecular Weight 394.4701
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of QUISINOSTAT

SMILES

CN1C=C(CNCC2CCN(CC2)C3=NC=C(C=N3)C(=O)NO)C4=C1C=CC=C4

InChI

InChIKey=PAWIYAYFNXQGAP-UHFFFAOYSA-N
InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)

HIDE SMILES / InChI

Molecular Formula C21H26N6O2
Molecular Weight 394.4701
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Quisinostat is an orally bioavailable potent histone deacetylase inhibitor, specifically selected due to its sustained inhibition of HDAC1 in solid tumor tissues and prolonged period of half-elimination from tissues. Phase 2 clinical trials are ongoing in patients with platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). Quisinostat is active in the treatment of patients with relapsed or refractory Sézary syndrome. The most common drug-related adverse events reported in this trial were: nausea, diarrhea, asthenia. Grade 3 adverse events were also reported: hypertension, lethargy and pruritus.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.11 nM [IC50]
0.33 nM [IC50]
0.37 nM [IC50]
0.46 nM [IC50]
0.64 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.828 ng/mL
6 mg 1 times / day steady-state, oral
dose: 6 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
QUISINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1.24 ng/mL
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
QUISINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.155 ng/mL
12 mg 1 times / day steady-state, oral
dose: 12 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
QUISINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.62 ng × h/mL
6 mg 1 times / day steady-state, oral
dose: 6 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
QUISINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
9.77 ng × h/mL
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
QUISINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
12.91 ng × h/mL
12 mg 1 times / day steady-state, oral
dose: 12 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
QUISINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
6 mg 1 times / day steady-state, oral
dose: 6 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
QUISINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
4.08 h
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
QUISINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.76 h
12 mg 1 times / day steady-state, oral
dose: 12 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
QUISINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
2009 Jul 1
Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
2009 Jun
JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
2009 Nov 15
The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
2009 Oct
Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor.
2010 Feb
Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.
2010 May
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
2011 Jul 14
Patents

Sample Use Guides

12 mg capsule on days 1, 3, and 5 of each week in a 21-day treatment cycle
Route of Administration: Oral
Quisinostat inhibited cell proliferation in all lung, breast, colon, prostate, brain, and ovarian tumor cell lines tested, with IC50 values ranging from 3.1 to 246 nM/L.
Substance Class Chemical
Created
by admin
on Mon Mar 31 20:57:22 GMT 2025
Edited
by admin
on Mon Mar 31 20:57:22 GMT 2025
Record UNII
9BJ85K1J8S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
QUISINOSTAT
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
JNJ 26481585
Preferred Name English
JNJ-26481585
Code English
Quisinostat [WHO-DD]
Common Name English
N-Hydroxy-2-[4-({[(1-methyl-1H-indol-3-yl)methyl]amino}methyl)piperidin-1-yl]pyrimidine-5-carboxamide
Systematic Name English
quisinostat [INN]
Common Name English
QUISINOSTAT [USAN]
Common Name English
5-PYRIMIDINECARBOXAMIDE, N-HYDROXY-2-(4-((((1-METHYL-1H-INDOL-3-YL)METHYL)AMINO)METHYL)-1-PIPERIDINYL)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1946
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C77912
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
PRIMARY
FDA UNII
9BJ85K1J8S
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
PRIMARY
ChEMBL
CHEMBL2105763
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
PRIMARY
WIKIPEDIA
Quisinostat
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
PRIMARY
INN
9452
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
PRIMARY
EPA CompTox
DTXSID90236376
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
PRIMARY
DRUG BANK
DB12985
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
PRIMARY
SMS_ID
100000166929
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
PRIMARY
CAS
875320-29-9
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
PRIMARY
EVMPD
SUB181224
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
PRIMARY
PUBCHEM
11538455
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
PRIMARY
USAN
XX-125
Created by admin on Mon Mar 31 20:57:22 GMT 2025 , Edited by admin on Mon Mar 31 20:57:22 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
It is approximately 500-fold more potent than vorinostat at inhibiting HDAC1.
IC50
TARGET->WEAK INHIBITOR
IC50
TARGET->WEAK INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
TARGET ORGANISM->INHIBITOR
TARGET->WEAK INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY